This week, US Magistrate Judge Richard Lloret directed Boehringer Ingelheim to disclose its launch plans for its biosimilar adalimumab, Cyltezo, as part of a long-running patent dispute with AbbVie, maker of the reference adalimumab, Humira.
This week, US Magistrate Judge Richard Lloret directed Boehringer Ingelheim (BI) to disclose its launch plans for its biosimilar adalimumab, Cyltezo, as part of a long-running patent dispute with AbbVie, maker of the reference adalimumab, Humira.
AbbVie filed a request to compel BI to detail its launch plans, saying that the plans are relevant to BI’s “unclean hands” defense, a legal defense that bars a party who is asking for a judgment from receiving the court’s help if that party has behaved unethically with respect to the subject of the lawsuit. According to BI, AbbVie’s strategy of acquiring what BI describes as overlapping, noninventive patents to hinder biosimilar competition could constitute unclean hands on AbbVie’s part.
According to AbbVie, BI’s public statements that it intends to launch Cyltezo prior to Humira’s patent expiry contradict BI’s claim that AbbVie’s patent estate has blocked BI from bringing its drug to the US market.
AbbVie also claims that BI is stockpiling Cyltezo ahead of a launch, an action that AbbVie says would infringe its patents.
BI, however, argues that the Biologics Price Competition and Innovation Act (BPCIA)’s provision of a 180-day notice of commercial marketing would be disrupted if the company were compelled to make its launch plans known to AbbVie.
Judge Lloret wrote in his memorandum that the BPCIA does not prevent or limit discovery in a biosimilar litigation, and that “Boehringer reads too much into the statute…the 180-day notice requirement is not designed to cloak launch plans with a broad ranging privilege against disclosure before the notice is filed.”
The judge also wrote that BI’s account of the motive behind and the consequences of AbbVie’s alleged misconduct related a patent thicket is central to its argument. The degree to which Humira’s patents delayed BI’s launch of its biosimilar “may have a legitimate impact on a fact-finder’s assessment of whether AbbVie has unclean hands,” he wrote. If BI argues that a patent thicket was created in order to delay competition and harm competitors, then it “would be unfair” for BI to refuse to quantify the damage caused.
Judge Lloret wrote that he will allow limited discovery and would require BI to state whether it contends that an alleged patent thicket delayed its launch plans for Cyltezo; if BI says that its plans were not delayed, “that will be an end to the discovery dispute.”
With respect to AbbVie’s concerns about BI’s alleged stockpiling of Cyltezo, however, the judge wrote that discovery would have minimal value and would pose a disproportionate burden, and he denied AbbVie’s request.
This latest development comes just weeks after Judge Lloret directed AbbVie to turn over to BI its documents related to its efforts to obtain patents on Humira. The judge agreed with BI that AbbVie had failed to produce numerous documents related to its patenting program and ordered AbbVie to “engage in rapid and punctilious compliance” with the order to produce the relevant materials.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.